Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data

OBJECTIVE: To assess the risk of hypertension in patients with migraine who received erenumab in clinical trials and in the postmarketing setting. BACKGROUND: Erenumab is a monoclonal antibody for migraine prevention that targets the calcitonin gene‐related peptide (CGRP) receptor. Hypertension is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dodick, David W., Tepper, Stewart J., Ailani, Jessica, Pannacciulli, Nicola, Navetta, Marco S., Loop, Brett, Zhang, Feng, Khodavirdi, Ani C., Mann, Allison, Abdrabboh, Ahmad, Kalim, Jawed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293040/
https://www.ncbi.nlm.nih.gov/pubmed/34591982
http://dx.doi.org/10.1111/head.14208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293040/
https://www.ncbi.nlm.nih.gov/pubmed/34591982
http://dx.doi.org/10.1111/head.14208

Ejemplares similares